Breaking News Instant updates and real-time market news.

BIIB

Biogen

$294.50

-18.72 (-5.98%)

06:07
12/19/18
12/19
06:07
12/19/18
06:07

Biogen traded down yesterday on 'not new' concerns, says Mizuho

Mizuho analyst Salim Syed attributes the selloff yesterday in shares of Biogen to "not new" and "simply re-surfaced" concerns of the Tecfidera inter partes review and Crenzumab's upcoming futility test. While these are both risks to Biogen, it is important to keep these two risks in perspective, Syed tells investors in a research note. Based on "actual, empirical data," there is only a 19% chance that Biogen's '514 patent is ruled unpatentable, says the analyst. And regarding the upcoming Roche/AC Immune Crenezumab futility analysis, Syed is "skeptical" to draw much read-through to Biogen's Aducanumab. The analyst keeps a Buy rating on Biogen with a $313 price target.

BIIB Biogen
$294.50

-18.72 (-5.98%)

12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/18/18
PIPR
12/18/18
NO CHANGE
Target $400
PIPR
Overweight
Piper says Biogen weakness on Tecfidera patent concerns a buying opportunity
Piper Jaffray analyst Christopher Raymond attributes today's weakness in Biogen (BIIB) shares to a competitor's research note that raised concerns about Mylan's (MYL) IPR challenge of Tecfidera's '514 dosing patent. While acknowledging that a worst case scenario does remove about $50 per share from his sum-of-the-parts valuation for Biogen, Raymond said his read of the current case, along with the fact that the '514 patent previously survived Forward Pharma's 2014 interference claim and Hayman Capital's IPR in 2015, lead him to view such scenario as "very low probability." The analyst, who views the weakness as a buying opportunity, keeps an Overweight rating and $400 price target on Biogen shares, which are down 7% to $291.31 in afternoon trading.
12/18/18
OPCO
12/18/18
NO CHANGE
Target $372
OPCO
Outperform
Biogen price target lowered to $372 from $380 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Biogen to $372 from $380 after co-hosting a call with a neurology expert to focus on several neuromuscular disorders and explore recent thoughts about spinal muscular atrophy. While Spinraza has a positive impact on maintaining independence, gene therapy and oral treatment are potential threats, and some reimbursement challenges facing Spinraza could be amplified with new modalities such as gene therapy, he contends. The analyst reiterates an Outperform rating on the shares.
12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Overweight
Piper says Biogen's diroximel fumarate opportunity being largely overlooked
After Biogen (BIIB) announced the submission of an NDA for diroximel fumarate, or BIIB098, Piper Jaffray analyst Christopher Raymond said he thinks investor sentiment largely overlooks the opportunity and that many discount it as "a Tecfidera IP play." However, he thinks BIIB098 could be "a pretty big deal" for Biogen's MS business as he believes the side effect profile improves measurably upon that of Tecfidera. Raymond, who contends that approval of this agent, which he notes is in-licensed from Alkermes (ALKS), could meaningfully reinvigorate Biogen's oral fumarate franchise, keeps an Overweight rating on Biogen shares.

TODAY'S FREE FLY STORIES

EPAY

Bottomline Technologies

$40.79

0.34 (0.84%)

05:21
10/16/19
10/16
05:21
10/16/19
05:21
Hot Stocks
Bottomline Technologies, Currencycloud partnership selected by Hargenant Group »

Bottomline Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 11

    Dec

CVLT

Commvault

$45.22

-0.24 (-0.53%)

05:20
10/16/19
10/16
05:20
10/16/19
05:20
Recommendations
Commvault analyst commentary  »

Commvault SaaS offering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 01

    Nov

AMZN

Amazon.com

$1,768.70

31.65 (1.82%)

05:19
10/16/19
10/16
05:19
10/16/19
05:19
Hot Stocks
AWS selected as preferred cloud provider by Old Mutual Limited »

Amazon Web Services, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

WATT

Energous

$3.29

0.09 (2.81%)

05:16
10/16/19
10/16
05:16
10/16/19
05:16
Hot Stocks
Energous enters partnership with ZPower »

Energous announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECD

Tech Data

$111.41

1.86 (1.70%)

, APO

Apollo Global

$39.39

0.63 (1.63%)

05:15
10/16/19
10/16
05:15
10/16/19
05:15
Periodicals
Apollo offered to acquire Tech Data for $130 per share in cash, Reuters reports »

Apollo Global Management…

TECD

Tech Data

$111.41

1.86 (1.70%)

APO

Apollo Global

$39.39

0.63 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

MOSC

Mosaic Acquisition

$10.29

0.005 (0.05%)

05:09
10/16/19
10/16
05:09
10/16/19
05:09
Initiation
Mosaic Acquisition initiated  »

Mosaic Acquisition…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASMB

Assembly Biosciences

$9.30

0.3 (3.33%)

05:06
10/16/19
10/16
05:06
10/16/19
05:06
Initiation
Assembly Biosciences initiated  »

Mizuho starts Assembly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 30

    Oct

AVAV

AeroVironment

$57.14

0.02 (0.04%)

05:00
10/16/19
10/16
05:00
10/16/19
05:00
Upgrade
AeroVironment rating change  »

AeroVironment upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$17.65

0.2 (1.15%)

04:57
10/16/19
10/16
04:57
10/16/19
04:57
Upgrade
Pure Storage rating change  »

Pure Storage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 17

    Dec

BOALY

Boral

$0.00

(0.00%)

04:56
10/16/19
10/16
04:56
10/16/19
04:56
Downgrade
Boral rating change  »

Boral downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Wedbush technology analyst to hold an analyst/industry webcast »

Technology Analyst…

JCOM

j2 Global

$96.34

0.47 (0.49%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
j2 Global management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 01

    Nov

  • 19

    Nov

AUY

Yamana Gold

$3.19

-0.1 (-3.04%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Yamana Gold management to meet with TD Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 25

    Oct

SCS

Steelcase

$18.15

0.29 (1.62%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Steelcase management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

TRVI

Trevi Therapeutics

$4.00

-0.55 (-12.09%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Trevi Therapeutics management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

CHWY

Chewy

$26.80

1.03 (4.00%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Chewy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

MREO

Mereo BioPharma

$3.58

0.08 (2.29%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Mereo BioPharma management to meet with SVB Leerink »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
BTIG to hold a forum »

Energy & Shipping…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
FBN Securities cannabis analysts to hold a breakfast meeting »

Analysts host Chairman…

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
FBN Securities media analyst to hold an analyst/industry conference call »

Media & Entertainment…

NXTC

NextCure

$26.93

-0.175 (-0.65%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
NextCure management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

PIRS

Pieris Pharmaceuticals

$3.22

0.01 (0.31%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Pieris Pharmaceuticals management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 31

    Oct

FLGT

Fulgent Genetics

$11.14

0.09 (0.81%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
Fulgent Genetics management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

  • 04

    Nov

ISEE

IVERIC bio

$0.99

-0.0016 (-0.16%)

04:55
10/16/19
10/16
04:55
10/16/19
04:55
Conference/Events
IVERIC bio management to meet with Wedbush »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.